European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
Hearing loss in hyperthyroid patients treated with teprotumumab (TepezzaR).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Santana Hager Murilo, Cottone Chloe, Guerra Navarro Paula Valeria, Dewan Ryan, Favre Nicole, Elrakhawy Mohamed, Carr Michele M
Аннотация
PURPOSE: To evaluate the association between teprotumumab use and hearing loss in hyperthyroid patients using real-world, population-level data.
METHODS: A retrospective cohort study using the TriNetX Collaborative Network was used to identify patients with hyperthyroidism (ICD-10 code E05) from 2006 to 2024. Two groups were established: one comprised of patients treated with teprotumumab and a control group of patients not treated with teprotumumab. Hearing loss was categorized as sensorineural (ICD-10 H90.A2, H90.A3, H90.A4, H90.A5), mixed (ICD-10 H90.A3, H90.A6, H90.A7, H90.A8), conductive (ICD-10 H90.0, H90.A1, H90.1, H90.2), or unspecified (ICD-10 H91.9). Cases of hearing loss occurring after teprotumumab initiation (in the treated group) or after hyperthyroidism diagnosis (in the control group) were recorded. Relative risk was calculated within a 95% confidence interval. Groups were propensity score matched for age and gender.
RESULTS: A total of 2,164 patients were included (1,082 per cohort; mean age 55.9 years, SD = 14.6), with 793 (73.3%) female and 258 (23.8%) male in each group. Sensorineural hearing loss occurred in 154 (14.2%) of Teprotumumab users versus 51 (4.7%) of controls (P < .001), corresponding to a relative risk (RR) of 3.15 (95% CI: 2.31-4.27). Unspecified hearing loss was reported in 78 (7.2%) Teprotumumab patients versus 47 (4.3%) controls (P = .006; RR = 1.66; 95% CI: 1.17-2.36). Conductive and mixed hearing loss could not be reliably analyzed due to small sample sizes (N < 10 per group).
CONCLUSION: Teprotumumab use is associated with a significantly increased risk of sensorineural and unspecified hearing loss in patients with hyperthyroidism. These findings support routine audiologic monitoring during treatment and highlight the need for prospective studies to investigate underlying mechanisms and preventative strategies.
METHODS: A retrospective cohort study using the TriNetX Collaborative Network was used to identify patients with hyperthyroidism (ICD-10 code E05) from 2006 to 2024. Two groups were established: one comprised of patients treated with teprotumumab and a control group of patients not treated with teprotumumab. Hearing loss was categorized as sensorineural (ICD-10 H90.A2, H90.A3, H90.A4, H90.A5), mixed (ICD-10 H90.A3, H90.A6, H90.A7, H90.A8), conductive (ICD-10 H90.0, H90.A1, H90.1, H90.2), or unspecified (ICD-10 H91.9). Cases of hearing loss occurring after teprotumumab initiation (in the treated group) or after hyperthyroidism diagnosis (in the control group) were recorded. Relative risk was calculated within a 95% confidence interval. Groups were propensity score matched for age and gender.
RESULTS: A total of 2,164 patients were included (1,082 per cohort; mean age 55.9 years, SD = 14.6), with 793 (73.3%) female and 258 (23.8%) male in each group. Sensorineural hearing loss occurred in 154 (14.2%) of Teprotumumab users versus 51 (4.7%) of controls (P < .001), corresponding to a relative risk (RR) of 3.15 (95% CI: 2.31-4.27). Unspecified hearing loss was reported in 78 (7.2%) Teprotumumab patients versus 47 (4.3%) controls (P = .006; RR = 1.66; 95% CI: 1.17-2.36). Conductive and mixed hearing loss could not be reliably analyzed due to small sample sizes (N < 10 per group).
CONCLUSION: Teprotumumab use is associated with a significantly increased risk of sensorineural and unspecified hearing loss in patients with hyperthyroidism. These findings support routine audiologic monitoring during treatment and highlight the need for prospective studies to investigate underlying mechanisms and preventative strategies.